Chemotherapy News and Research

Latest Chemotherapy News and Research

FoXTROT results: preoperative chemo could become new standard

Preoperative chemotherapy is a feasible option for resectable advanced colon cancer, show results of the FoXTROT trial.

1 Nov 2012

Treatment rate high at end of life for prostate cancer patients

Approximately one-third of men with castration-resistant prostate cancer receive some form of treatment in the last 3 months of life, show US study results.

1 Nov 2012

Regular blood test may help predict survival in patients with Merkel cell carcinoma

A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology's 54th Annual Meeting.

1 Nov 2012

Study shows increased risk of local recurrence in women with triple negative breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of local recurrence than similar women whose disease is not classified as triple-negative.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Gene variant predicts lymphoma treatment response

German researchers have identified a gene variant that significantly influences the outcome of methotrexate therapy for primary central nervous system lymphoma.

31 Oct 2012

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the European Commission has granted conditional marketing authorisation for ADCETRIS (brentuximab vedotin) for two indications.

31 Oct 2012

Uterine cancer recurrence risk after hysterectomy increases due to delay in radiation therapy

Waiting too long after a hysterectomy to begin radiation therapy may increase the risk of uterine cancer recurrence, according to a new study from researchers at Henry Ford Hospital in Detroit.

31 Oct 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Oct 2012

Blocking RSK protein activity could improve treatment of skin cancers

Blocking the action of a particular protein in our skin could improve the treatment of skin cancers, according to a study published in Oncogene yesterday by Philippe Roux, a researcher at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC).

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

30 Oct 2012

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

29 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Living examples of hope and determination against cancer

Their battle with cancer is not the only thing that unites the Labrada sisters of Houston who are now cancer-free and strong advocates for women taking charge of their bodies.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

Triapine shows promise in treating breast cancer

Students at Tennessee Tech University are developing and testing a series of chemical compounds that show promise of stopping cancer in its tracks.

29 Oct 2012

Idea of nuclear reprogramming holds promise for repairing damaged tissue

The idea of taking a mature cell and removing its identity (nuclear reprogramming) so that it can then become any kind of cell, holds great promise for repairing damaged tissue or replacing bone marrow after chemotherapy.

29 Oct 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

FoXTROT results: preoperative chemo could become new standard

Treatment rate high at end of life for prostate cancer patients

Regular blood test may help predict survival in patients with Merkel cell carcinoma

Study shows increased risk of local recurrence in women with triple negative breast cancer

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Gene variant predicts lymphoma treatment response

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Uterine cancer recurrence risk after hysterectomy increases due to delay in radiation therapy

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

Blocking RSK protein activity could improve treatment of skin cancers

Nabilone shows promise in treating diabetic neuropathy

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Living examples of hope and determination against cancer

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

Triapine shows promise in treating breast cancer

Idea of nuclear reprogramming holds promise for repairing damaged tissue

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in